M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Phase 2

Completed

Conditions: Classic Hodgkin Lymphoma
Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Lugano Classification Stage III Hodgkin Lymphoma AJCC v8

Interventions: Drug: Bleomycin
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Biological: Rituximab
Drug: Vinblastine

First Posted Date: 2008-04-09

Last Posted Date: 2020-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT00654732

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Phase 2

Completed

Conditions: Multiple Myeloma
Primary Amyloidosis

Interventions: Drug: Melphalan
Procedure: Stem Cell Infusion
Behavioral: Questionnaires
Drug: Granulocyte-colony stimulating factor (G-CSF)
Procedure: Apheresis

First Posted Date: 2008-04-03

Last Posted Date: 2020-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00651937

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Not Applicable

Completed

Conditions: Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Aprepitant
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Rituximab
Drug: Ondansetron

First Posted Date: 2008-04-03

Last Posted Date: 2013-07-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00651755

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Dasatinib in Resectable Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Dasatinib

First Posted Date: 2008-04-03

Last Posted Date: 2022-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00652574

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations

Active, not recruiting

Conditions: Rectal Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-04-01

Last Posted Date: 2024-08-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00648635

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Procedure: Axillary Reverse Mapping

First Posted Date: 2008-03-27

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00645541

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Asian Youth and Tobacco Control Survey

Completed

Conditions: Tobacco Use
Smoking

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-03-25

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 617

Registration Number: NCT00642317

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: RAD001
Drug: Erlotinib

First Posted Date: 2008-03-21

Last Posted Date: 2023-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00640978

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Withdrawn

Conditions: Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: Placebo
Drug: Femara

First Posted Date: 2008-03-13

Last Posted Date: 2016-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00634894

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

Phase 3

Terminated

Conditions: Advanced Cancer
Solid Tumors

Interventions: Drug: Methadone
Drug: Morphine

First Posted Date: 2008-03-12

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT00634010

Locations: 🇺🇸
LBJ General Hospital, Houston, Texas, United States
🇺🇸
The Michael E. DeBakey V.A. Medical Center, Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy